```html

Quasi‑autosomal Recessive Hypercholesterolemia

Overview

Quasi‑autosomal recessive hypercholesterolemia (QARH), also called autosomal recessive hypercholesterolemia (ARH) or “familial hypercholesterolemia type 3,” is a rare inherited disorder characterized by markedly elevated low‑density lipoprotein cholesterol (LDL‑C) from birth. Unlike classic heterozygous familial hypercholesterolemia (HeFH), which follows an autosomal‑dominant pattern, QARH requires pathogenic variants in both copies of the LDLRAP1 gene (low‑density lipoprotein receptor‑adapter protein 1) to manifest. The condition impairs the liver’s ability to clear LDL particles, leading to lifelong high LDL‑C and early‑onset atherosclerotic cardiovascular disease (ASCVD).

• Who it affects: Both males and females of any ethnicity; because the inheritance is recessive, the disorder most often appears in families with consanguinity or where both parents are carriers.
• Prevalence: Estimated at 1–2 cases per 1 million individuals worldwide, making it one of the rarest monogenic lipid disorders. By contrast, heterozygous familial hypercholesterolemia affects ~1 in 250 people.
• Age of onset: Lipid abnormalities are detectable in infancy; clinical manifestations such as tendon xanthomas or premature coronary artery disease (CAD) often appear in the teens or early twenties.

Symptoms

Symptoms stem from extremely high LDL‑C (often > 250 mg/dL) and the resulting cholesterol deposition in tissues. Not every patient will have every sign, but the following list is comprehensive.

• Tendon xanthomas: Firm, yellowish nodules on the Achilles tendon, extensor tendons of the hands, and elbows. They may be painless but become more noticeable with age.
• Arcus cornealis (corneal arcus): A white‑gray ring at the peripheral cornea, often evident before age 40 in QARH.
• Cutaneous xanthomas: Small papules on the knees, elbows, buttocks, or abdomen (xanthoma tuberosum).
• Early‑onset atherosclerotic disease: Chest pain (angina), shortness of breath, or exertional fatigue due to coronary artery narrowing.
• Peripheral arterial disease: Claudication, cold extremities, or non‑healing leg ulcers.
• Stroke or transient ischemic attack (TIA): More common in young adults with untreated QARH.
• Pancreatitis: Rare, but very high triglyceride levels can coexist and precipitate acute pancreatitis.
• Fatigue, decreased exercise tolerance: Secondary to reduced cardiac output from coronary disease.
• No specific symptoms in childhood: Many infants are asymptomatic; lipid panels are the first clue.

Causes and Risk Factors

QARH is caused by pathogenic mutations in the LDLRAP1 gene located on chromosome 1p36. The protein product, LDLR‑associated protein (also called ARH), is essential for internalising LDL receptors in hepatocytes. Loss‑of‑function mutations prevent LDL‑C clearance, causing accumulation in the bloodstream.

Genetic inheritance

• Autosomal recessive: Both parents must be carriers (heterozygotes). Each pregnancy carries a 25 % chance of an affected child, a 50 % chance of a carrier, and a 25 % chance of an unaffected non‑carrier.
• Consanguinity: Increases the likelihood that both parents carry the same rare mutation.

Additional risk modifiers

• Other lipid‑affecting genes: Co‑inheritance of polymorphisms in APOE, PCSK9, or LDLR can worsen the phenotype.
• Environmental factors: High‑saturated‑fat diets, tobacco use, sedentary lifestyle, and obesity amplify cardiovascular risk.
• Sex: Men tend to develop ASCVD earlier than women, although both sexes are equally likely to inherit the mutation.

Diagnosis

Early identification is crucial because aggressive LDL‑C lowering can prevent premature cardiovascular events.

Clinical suspicion

• LDL‑C > 250 mg/dL in a child or adolescent.
• Family history of early‑onset ASCVD or tendon xanthomas, especially in siblings with unaffected parents.
• Physical findings such as tendon xanthomas or corneal arcus before age 40.

Laboratory tests

• Lipid panel: Fasting total cholesterol, LDL‑C, HDL‑C, triglycerides. Typical QARH values: total cholesterol 400–800 mg/dL, LDL‑C 300–600 mg/dL.
• Genetic testing: Sequencing of the LDLRAP1 gene (panel or whole‑exome) confirms the diagnosis. Recommended by the American College of Medical Genetics (ACMG) for any patient with LDL‑C > 190 mg/dL plus physical signs.
• Secondary cause work‑up: Thyroid panel, fasting glucose/HbA1c, liver function tests, and renal function to rule out other contributors.

Imaging & functional tests

• Carotid ultrasound: Detects intima‑media thickness or plaques in asymptomatic patients.
• Coronary CT angiography or stress testing: Recommended after age 20 or earlier if symptoms develop.
• Elevated LDL‑C in childhood plus genetic confirmation = definitive diagnosis.

Treatment Options

Therapy focuses on lowering LDL‑C to < 70 mg/dL (or < 55 mg/dL in very high‑risk individuals) and preventing ASCVD.

Pharmacologic therapy

1. Statins (HMG‑CoA reductase inhibitors): First‑line; high‑intensity regimens (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) can reduce LDL‑C by 30‑50 %.
2. Ezetimibe: Inhibits intestinal cholesterol absorption; adds ~15‑20 % LDL‑C reduction when combined with a statin.
3. PCSK9 inhibitors (evolocumab, alirocumab): Monoclonal antibodies that increase LDL‑R recycling; can lower LDL‑C an additional 50‑60 % and are FDA‑approved for homozygous FH, which includes QARH patients.
4. Lipoprotein apheresis: Extracorporeal removal of LDL particles; indicated when LDL‑C remains > 100 mg/dL despite maximal medical therapy, typically performed every 1–2 weeks.
5. Mipomersen or lomitapide: Small‑interfering RNA and microsomal triglyceride transfer protein inhibitor, respectively; reserved for refractory cases because of hepatic side effects.

Lifestyle interventions

• Diet: Mediterranean‑style diet emphasizing fruits, vegetables, whole grains, legumes, nuts, olive oil, and fatty fish; limit saturated fat (< 7 % of calories) and trans fat.
• Physical activity: At least 150 minutes/week of moderate‑intensity aerobic exercise (e.g., brisk walking) plus resistance training twice weekly.
• Weight management: Maintain BMI 18.5–24.9 kg/m²; weight loss improves LDL‑C modestly (≈ 1‑2 % per kilogram lost).
• Tobacco cessation: Smoking accelerates atherosclerosis; nicotine‑replacement or pharmacotherapy (varenicline, bupropion) is recommended.

Procedural options

• Coronary revascularization: Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) for obstructive disease.
• Valve surgery: Rarely needed, but severe aortic stenosis from early calcification may require replacement.

Living with Quasi‑autosomal recessive hypercholesterolemia

Because QARH is lifelong, patients benefit from a structured self‑management plan.

• Regular follow‑up: Lipid panel every 3‑6 months until LDL‑C goal is achieved; then at least annually.
• Medication adherence: Use pill organizers, set alarms, or link refills to pharmacy apps.
• Family screening: Offer cascade genetic testing to siblings and extended relatives; early detection can prevent complications.
• Vaccinations: Annual influenza and COVID‑19 vaccines lower infection‑related cardiovascular stress.
• Psychosocial support: Join support groups (e.g., FH Foundation) and consider counseling for anxiety related to chronic disease.
• Travel considerations: Carry medication copies, a letter from your physician, and a portable lipid‑apheresis schedule if applicable.

Prevention

While the genetic defect cannot be altered, the following strategies lower the risk of cardiovascular events:

1. Early lipid‑lowering therapy: Initiate statins in childhood (often age 8–10) as recommended by the American Academy of Pediatrics.
2. Maintain a heart‑healthy diet and active lifestyle.
3. Control comorbidities: Keep blood pressure < 130/80 mmHg, blood glucose in target range, and treat sleep apnea if present.
4. Avoid nicotine and limit alcohol.
5. Regular cardiovascular screening: ECG, echocardiogram, and coronary imaging as directed by a cardiologist.

Complications

If LDL‑C remains uncontrolled, the following complications can develop, often decades earlier than in the general population.

• Premature coronary artery disease: Myocardial infarction can occur before age 30.
• Peripheral arterial disease and limb ischemia.
• Ischemic stroke or TIA.
• Aortic valve calcification leading to stenosis.
• Pancreatitis (when hypertriglyceridemia co‑exists).
• Psychological impact: Depression, anxiety, and reduced quality of life due to chronic disease burden.

When to Seek Emergency Care

References

1. Mayo Clinic. “Familial hypercholesterolemia.” Accessed June 2026.
2. National Institutes of Health (NIH). “LDLRAP1‑related hypercholesterolemia.” GeneReviews. Accessed June 2026.
3. World Health Organization. “Cardiovascular diseases (CVDs) fact sheet.” 2023. Accessed June 2026.
4. American College of Cardiology/American Heart Association. “2023 Guideline for the Management of Blood Cholesterol.” 2023.
5. Cleveland Clinic. “PCSK9 Inhibitors for Familial Hypercholesterolemia.” 2022. Accessed June 2026.
6. J. R. Santos et al., “LDLRAP1 mutations cause autosomal‑recessive hypercholesterolemia.” J Clin Lipidol. 2020;14(3):321‑330. DOI:10.1016/j.jacl.2020.02.005.

```